| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts; 2 Department of Surgery (Urology), Yale University School of Medicine, New Haven, Connecticut; and 3 Departments of Urology, Microbiology, Dermatology and Pharmacology, 4 NYU Cancer Institute, New York University Medical School, New York, New York
Requests for reprints: Dario C. Altieri, Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, LRB428 364 Plantation Street, Worcester, MA 01605. Phone: 508-856-5775; Fax: 508-856-5792; E-mail: dario.altieri{at}umassmed.edu.
Gene signatures that predict aggressive tumor behavior at the earliest stages of disease, ideally before overt tissue abnormalities, are urgently needed. To search for such genes, we generated a transgenic model of survivin, an essential regulator of cell division and apoptosis overexpressed in cancer. Transgenic expression of survivin in the urinary bladder did not cause histologic abnormalities of the urothelium. However, microarray analysis revealed that survivin-expressing bladders exhibited profound changes in gene expression profile affecting extracellular matrix and inflammatory genes. Following exposure to a bladder carcinogen, N-butyl-N-(4-hydroxybutyl) nitrosamine (OH-BBN), survivin transgenic animals exhibited accelerated tumor progression, preferential incidence of tumors as compared with premalignant lesions, and dramatically abbreviated survival. Conversely, transgenic expression of a survivin Thr34
Ala dominant-negative mutant did not cause changes in gene expression or accelerated tumor progression after OH-BBN treatment. Therefore, survivin expression induces global transcriptional changes in the tissue microenvironment that may promote tumorigenesis. Detection of survivin or its associated gene signature may provide an early biomarker of aggressive tumor behavior before the appearance of tissue abnormalities.
This article has been cited by other articles:
![]() |
J. Thomas, T. Liu, M. A. Cotter, S. R. Florell, K. Robinette, A. N. Hanks, and D. Grossman Melanocyte Expression of Survivin Promotes Development and Metastasis of UV-Induced Melanoma in HGF-Transgenic Mice Cancer Res., June 1, 2007; 67(11): 5172 - 5178. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Liu, D. P. Evanoff, X. Chen, and Y. Luo Urinary Bladder Epithelium Antigen Induces CD8+ T Cell Tolerance, Activation, and Autoimmune Response J. Immunol., January 1, 2007; 178(1): 539 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-H. Peng, P. Karna, R. M. O'Regan, X. Liu, R. Naithani, R. M. Moriarty, W. C. Wood, H.-Y. Lee, and L. Yang Down-Regulation of Inhibitor of Apoptosis Proteins by Deguelin Selectively Induces Apoptosis in Breast Cancer Cells Mol. Pharmacol., January 1, 2007; 71(1): 101 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Black, G. A. Brown, and C. P. Dinney Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5528 - 5535. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Xia and D. C. Altieri Mitosis-Independent Survivin Gene Expression In vivo and Regulation by p53. Cancer Res., April 1, 2006; 66(7): 3392 - 3395. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |